Receiving-site gap assessmentQuality agreement reviewFirst-lot release records
Home / Deviations and Investigations at Transfer Handover

Deviations and Investigations at Transfer Handover

Track unresolved events and their implications for material disposition and contract manufacturer responsibilities.

Which observation started the investigation?

Keep the original observation, product or sample identity, date and applicable requirement together. Record whether the concern is a departure from an agreed activity, a result outside a specification or a discrepancy that still needs explanation. These situations can require different owners and investigations. FDA’s guidance on pharmaceutical out-of-specification results addresses how relevant laboratory findings are assessed. A later acceptable result still needs to be interpreted within the full investigation history.

FDA (2022) · Investigating out-of-specification pharmaceutical test results

A circular feed bowl and guide rails are visible beside a row of containers.
Container feed and guide railsThe overview distinguishes container handling from the separate decision to release a particular lot.
Image creditsCompany footage
Horizontal shelves are visible through a round observation window in a piece of enclosed equipment.
Chamber observation windowA recorded equipment view gives context when reviewing which facility a transfer dossier describes.
Image creditsCompany footage

Who can close the outstanding questions?

Identify who has the original evidence, who can authorise further review, and who can decide the disposition of any linked material. Agree how the customer and receiving organisation will receive updates if the investigation continues after the planned handover date. Each interim report should say what is known, what remains open and which approval depends on the outcome, using the issue identifier already known to all parties.

FDA (2016) · Quality agreements in contract drug manufacturing

What if the sending site already issued a revised report?

Place the revised report alongside the original and ask for the stated reason, authorisation and date of the amendment. If the revision fixes a transcription error, the underlying record should allow the receiving quality team to see that. If it reflects a new assessment, keep the decision rationale and supporting evidence linked to both versions. Before commercial release, ask the designated reviewer for an explicit disposition of all affected material and record any remaining follow-up obligations.

FDA (2018) · Data integrity and drug CGMP questions and answers

Worked example

If an investigation spans two sites with separate tracking systems, record both local event IDs under a common reference. Identify which site owns the final conclusion and which receives closure evidence. That decision keeps the receiving team from closing its action before the responsible review.

Prepare your inquiry

An investigation can cross a site boundary only if ownership and the original evidence remain traceable.

Select the items you want to ask about.

Certificates of analysis

For a transferred lyophilized powder project, compare the issuing site, lot identifier and certificate version with the agreed first-lot release record.

Read a COA